Biological background for non-smoker lung adenocarcinoma : Why do EGFR somatic mutations accumulate on lung adenocarcinoma and on Asian ethnics?

21世纪，肺癌的治疗已经发生了革命性的变化。在亚裔人群中发现了高发的体细胞EGF受体突变，导致口服TKI进行靶向治疗。为了进一步了解肺癌的生物学背景，我们利用NOD-SCID小鼠成功地形成了具有临床相关EGFR突变的缓慢生长的异种移植瘤。我们通过对携带EGFR突变的患者的全基因组SNP微阵列分析和对携带EGFR突变的家族性肺癌患者的外显子组分析，确定了可能与肺癌体细胞EGFR突变选择有关的候选基因。这些发现可以在未来提供更好的治疗和预防性应用。

Therapy for lung cancer has been revolutionized in 21st century. The discovery of somatic EGF receptor mutation with high incidence among Asian ethnics led to the targeted therapy by oral TKI administration. To further understand the biological background of lung cancer we succeeded in slow growing xenograft formation with clinical relevant EGFR mutation using NOD-SCID mice. We have identified candidate genes that could relate to somatic EGFR mutation selection in lung cancer through whole genome SNP microarray analysis of patients harboring EGFR mutations, and exome analysis among patients of familial lung cancer members with EGFR mutations. These findings could provide better treatment and preventive applications in the future.